AbbVie Inc (NYSE:ABBV) investors are concerned amid an impending expiration of the company’s best-selling drug Humira, which brought in $4.7 billion in sales in the second quarter of 2017. Humira sales are expected to decline even before its patent expiration. The drug is under threat from a recently approved JAK-1 inhibitor Olumiant in Europe. Analysts think that AbbVie will continue to earn a lot of revenue from Imbruvica, but the problem is that the Johnson & Johnson has its selling rights outside the US.
AbbVie Inc (NYSE:ABBV) is currently working on JAK-1 Upadacitinib. The company also entered the HCV market with Mavyret.